Key Points
- Insider sale: Apellis General Counsel David Watson sold 5,000 shares on December 16 at an average price of $24.49 for $122,450, leaving him with 103,730 shares—a 4.6% reduction in his position (SEC filing).
- Strong quarter but mixed outlook: Apellis reported Q results with $1.67 EPS (vs. $1.03 est.) and $458.6M revenue (up 133% YoY), yet analysts still forecast -1.7 EPS for the current fiscal year and the consensus rating is a "Hold" with a $33.06 target.
- Stock and valuation snapshot: Shares opened at $24.48 (down ~2.9%), the company has a ~$3.10 billion market cap and a P/E of 78.97, with a one-year range of $16.10–$35.57.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) General Counsel David Watson sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $24.49, for a total value of $122,450.00. Following the sale, the general counsel directly owned 103,730 shares of the company's stock, valued at approximately $2,540,347.70. This trade represents a 4.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Apellis Pharmaceuticals Stock Down 2.9%
Shares of NASDAQ APLS opened at $24.48 on Friday. The stock has a market capitalization of $3.10 billion, a P/E ratio of 78.97 and a beta of 0.37. Apellis Pharmaceuticals, Inc. has a one year low of $16.10 and a one year high of $35.57. The firm's 50 day simple moving average is $23.05 and its two-hundred day simple moving average is $22.56. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10.
Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The company had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same quarter last year, the firm earned ($0.46) EPS. The firm's quarterly revenue was up 133.0% compared to the same quarter last year. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.
Institutional Investors Weigh In On Apellis Pharmaceuticals
Hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock valued at $33,000 after purchasing an additional 855 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company's stock worth $46,000 after buying an additional 1,373 shares during the last quarter. Osaic Holdings Inc. increased its position in Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company's stock valued at $47,000 after buying an additional 1,570 shares in the last quarter. Allworth Financial LP increased its position in Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company's stock valued at $50,000 after buying an additional 857 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Apellis Pharmaceuticals during the third quarter valued at $64,000. Institutional investors own 96.29% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on APLS shares. Wall Street Zen raised shares of Apellis Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, November 8th. Citigroup decreased their price objective on shares of Apellis Pharmaceuticals from $52.00 to $45.00 and set a "buy" rating on the stock in a research report on Friday, October 31st. Wolfe Research started coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 6th. They set a "peer perform" rating for the company. TD Cowen reduced their price target on Apellis Pharmaceuticals from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Friday, October 31st. Finally, Robert W. Baird upped their price target on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an "outperform" rating in a research report on Friday, October 31st. Ten research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $33.06.
Get Our Latest Analysis on Apellis Pharmaceuticals
About Apellis Pharmaceuticals
(
Get Free Report)
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
